Literature DB >> 3576672

Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporine.

E Carlesen, H Prydz.   

Abstract

At present cyclosporine is the immunosuppressive agent of choice. Although its introduction has led to an improvement in graft and patient survival, an increase in thromboembolic complications has been reported. We have shown previously that exposure to CsA of TPA- and PHA-stimulated monocyte and mononuclear blood cell cultures increased their cellular thromboplastin activity significantly. In this article we report that CsA enhances the synthesis and release of factor VII, as well as the release of thromboplastin, from LPS- and PHA-stimulated monocytes and whole mononuclear cell cultures. The increase in activity of both factors requires de novo protein synthesis. The synthesis and release of thromboplastin and factor VII from the same cells allow efficient formation of their stoichiometric complex, the most potent trigger of blood coagulation known. The enhancement of their synthesis and release by CsA is therefore potentially very important in the pathogenesis of thromboembolic complications.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3576672     DOI: 10.1097/00007890-198704000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

Review 1.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Differential effect of alpha-interferon and gamma-interferon on thromboplastin response in monocytes and endothelial cells.

Authors:  E Carlsen; M B Stinessen; H Prydz
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.